Razavi S, Nazem G, Mardani M, Esfandiari E, Esfahani S, Salehi H (2015) Neurotrophic factors and their effects in the treatment of multiple sclerosis. Adv Biomed Res 4(1). https://doi.org/10.4103/2277-9175.151570 We found six studies including a total of 597 people living with vascular dementia. The method of Cerebrolysin treatment differed across studies, with varying strengths of Cerebrolysin and treatment durations. The studies reported that Cerebrolysin had beneficial effects on memory and thinking and on daily functioning. There was no reported risk of side effects with treatment. None of the studies described quality of life of people living with vascular dementia or their caregivers. Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118

A relatively unique discovery about the properties of Cerebrolysin is that it can help to control pain. Research in rats shows that Cerebrolysin can help to reduce pain and other symptoms associated with migraine. Measurement of pro-inflammatory cytokines like TNF-alpha and IL-1B shows that these pain-causing molecules are decreased following administration of Cerebrolysin[19]. These studies were carried out on rat models of chronic migraine, suggesting that Cerebrolysin may be particularly useful in those who suffer the most from these debilitating headaches. Given the difficulty of treating migraines, particularly chronic migraines, this finding represents an important step toward improved well-being for tens of thousands of individuals. Cerebrolysin can benefit patients with mild to severe brain injuries. After severe traumatic brain injury, Cerebrolysin administration results in decreased mortality rate, better outcomes, and improved functionality of the affected area. In severe brain injuries, Cerebrolysin has shown more efficacy than other pharmacological agents.Fragoso YD, Dantas DC (2002) Cerebrolysin for Alzheimer’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd003801 Ladurner G, Kalvach P, Moessler H (2005) Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna) 112(3):415–428. https://doi.org/10.1007/s00702-004-0248-2 Shamalov NA, Stakhovskaia LV, Burenchev DV, Kichuk IV, Tvorogova TV, Botsina A, Smychkov AS, Kerbikov OB, Moessler H, Novak P, Skvortsova VI (2010) The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 110(12 Pt 2):34–37 In this blog designed for a scientific audience we will look at a putative treatment Something done with the aim of improving health or relieving suffering. For example, medicines, surgery, psychological and physical therapies, diet and exercise changes. for vascular dementia called Cerebrolysin. Martin Taylor-Rowan (MTR) and Bogna Drozdowska (BD), two researchers working in the field of vascular dementia, will interpret the clinical significance Clinical significance is the practical importance of an effect (e.g. a reduction in symptoms); whether it has a real genuine, palpable, noticeable effect on daily life. It is not the same as statistical significance. For instance, showing that a drug lowered the heart rate by an average of 1 beat per minute would not be clinically significant, as it is unlikely to be a big enough effect to be important to patients and healthcare providers. of the existing data Data is the information collected through research.. Martin and Bogna have differing views on the topic, so Terry Quinn (TQ – co-ordinating editor Cochrane Dementia) will ‘referee’ and give some opening and closing thoughts.

After the administration of Cerebrolysin, the neuronal functions and different neuronal conditions show a significant improvement. Here are the principal components of Cerebrolysin: Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059 Terry has a broad research portfolio, his principal research interests are around trial methodology, functional assessment and neuropsychological consequences of stroke. Rare cases of adverse reactions to Cerebrolysin may include fatigue, headaches, dizziness, insomnia, etc. Onose G, Mureşanu DF, Ciurea AV, Daia Chendreanu C, Mihaescu AS, Mardare DC, Andone I, Spânu A, Popescu C, Dumitrescu A, Popescu M, Grigorean V, Ungur B, Marinescu F, Colibbeanu I, Onose L, Haras M, Sandu A, Spircu T (2009) Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life 2(4):350–360

Our source of Cerebrolysin is from an EU Ever Pharma registered distributor - so the box is in German

Within the VaD rubric, the following has been proposed as a classification of the subtypes of VaD ( O'Brien 2015):In adults with traumatic brain injury, limited research from a double-blinded, placebo-controlled, randomized phase 2 pilot study has revealed that Cerebrolysin can improve cognitive function, motor control, and long-term memory[17]. This study was carried out in a limited population suffering from mild traumatic brain injury, but suggests that Cerebrolysin has a significant benefit, when combined with standard therapy, in recovery following neurological injury. These findings follow research in rats showing that Cerebrolysin improves sensory-motor function following brain injury[18]. Cerebrolysin in Pain Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768

Cerebrolysin has an excellent safety record. Unless taken in large amounts (>10 ml), adverse reactions are mild and rare. Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H (2016) Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med 11(5):2015–2020. https://doi.org/10.3892/etm.2016.3139 The drug is injected slowly. If the injection is made too fast, in rare cases, there can be a feeling of heat, sweating, dizziness, heart palpitations, or arrhythmia. Similar pain-reducing effects have been seen in rat models of neuropathic (nerve) pain. Administration of Cerebrolysin in this setting helps to reduce mechanical pain, but not inflammatory pain[20]. However, the study was not carried out long enough to fully rule out an effect on inflammatory pain. What makes this finding significant is that it shows a reduction in pain that likely results from the neurotrophic (nerve plasticity) properties of Cerebrolysin as well as from its neurogenic (nerve growth) properties. Cerebrolysin Summary Research shows that Cerebrolysin readily crosses the blood-brain barrier in sufficient concentrations to produce pharmacodynamic effects in the brain and spinal cord. The full molecular action of each component of Cerebrolysin has yet to be elucidated, but progress is being made in this area. What Does Cerebrolysin Do?The side effects of Cerebrolysin are rare and of mild intensity. The most frequently reported adverse reactions with Cerebrolysin are dizziness, headache, sweating, and nausea. So I just want to say that I pay a lot of attention and time to decide whether a substance is affecting me or if it is simply placebo.